Treatment of Patients With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before, Under and After Radiation and With Adding Cetuximab to K-RAS Wild-type Patients

• Status: Unknown status
• Trial end date: 2017-07-01
• Target enrollment: 0
• Participant gender: All

Summary

response rate to adding cetuximab, oxaliplatin and capecitabine to radiation for advanced rectum cancer

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Copenhagen University Hospital at Herlev
• Treatments: Capecitabine; Cetuximab; Oxaliplatin

Criteria

Inclusion Criteria:

• advanced rectum cancer

Exclusion Criteria:

• prior radiation